The hospital chain’s consolidated net profit fell 47.2% year-on-year to ₹41.5 crore in the first quarter of FY27 from ₹78.6 crore a year earlier.
Revenue from operations, however, rose 35.3% to ₹1,179.5 crore from ₹871.6 crore in the same period last year.
Operating profit also increased, with EBITDA rising 16% to ₹223.4 crore. However, margins came under pressure, with EBITDA margin narrowing to 18.9% from 22.1% a year ago.
Hospital network expands
KIMS said its total bed capacity increased to 7,459 beds as of June 30, 2026, compared with 6,464 beds at the end of March and 5,499 beds a year earlier.
Chairman and Managing Director B. Bhaskara Rao said the company began FY27 on a strong note with the addition of a new hospital in Palakkad, Kerala.
He said newer hospitals continued to perform well, with some facilities carrying out complex procedures, including lung transplants.
The company also reported healthy growth in both outpatient and inpatient visits during the quarter, supporting revenue growth.
Fundraising and expansion plans
Separately, KIMS said it has utilised part of the ₹1,500 crore raised through a qualified institutional placement (QIP) completed in FY26. The remaining funds have been temporarily invested in mutual funds and placed in a monitoring account.
The company’s board and shareholders have also approved raising up to ₹600 crore through the issue of 77 lakh convertible warrants to promoters and promoter group entities.
The warrants, priced at ₹779 each, can be converted into equity shares within 18 months, subject to regulatory approvals.
During the quarter, KIMS also entered into a hospital operations and management agreement with a healthcare services company, giving it control over hospital operations. The transaction has been accounted for as a business combination under accounting standards.
Shares of Krishna Institute of Medical Sciences closed 2.65% higher at ₹826 on the NSE on Monday ahead of the June quarter earnings announcement.
Also Read: Stocks to Watch for August 4: Paytm, DLF, Torrent Power, GSK Pharma and more
